GeoVax Labs Stock
StockStockPrice
Frequently asked questions
What is GeoVax Labs's market capitalization?
What is the Earnings Per Share (EPS) for GeoVax Labs?
What are the analyst ratings and target price for GeoVax Labs's stock?
What is GeoVax Labs's revenue over the trailing twelve months?
What is the EBITDA for GeoVax Labs?
What is the free cash flow of GeoVax Labs?
What is the 5-year beta of GeoVax Labs's stock?
How many employees does GeoVax Labs have, and what sector and industry does it belong to?
What is the free float of GeoVax Labs's shares?
Financials
Market Cap
$26.77M5Y beta
3.31EPS (TTM)
-$13.05Free Float
8.48MRevenue (TTM)
$300.68KEBITDA (TTM)
-$27.16MFree Cashflow (TTM)
-$23.02MPricing
Analyst Ratings
The price target is $72.00 and the stock is covered by 2 analysts.
Buy
2
Hold
0
Sell
0
Information
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
17
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker